Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T14:56:05.301Z.
Calculation as of: 2026-10-06T14:56:05.301Z.
Quote observation: 2026-10-06T14:55:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ee881eee59918e8cff759d9372c22030baed04f147f6b571d3011c58a892a573
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$93.81M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$88.21M
EV/Sales Ratio
2.99x
TTM Avg
2.76x
3Y Avg
2.60x
5Y Avg
2.86x
Market Cap
$95.95M
EV/Sales Ratio
47.55x
TTM Avg
38.61x
3Y Avg
38.86x
5Y Avg
28.17x
Market Cap
$96.73M
EV/Sales Ratio
29.38x
TTM Avg
95.40x
3Y Avg
61.44x
5Y Avg
43.17x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | $91.68M | N/A | N/A | N/A | N/A |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $93.81M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $92.14M | 2.52x | 1.93x | 2.28x | 2.11x |
| Equillium, Inc. (EQ)vs › | $90.41M | N/A | 3.31x | 1.36x | 1.36x |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 2.99x | 2.76x | 2.60x | 2.86x |
| Conexeu Sciences Inc. (CNXU)vs › | $87.27M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 0.99x | 1.01x | 0.60x | 0.55x |
| Korro Bio, Inc. (KRRO)vs › | $95.95M | 47.55x | 38.61x | 38.86x | 28.17x |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $96.73M | 29.38x | 95.40x | 61.44x | 43.17x |
| Cardiff Oncology, Inc. (CRDF)vs › | $85.17M | 150.45x | 202.08x | 199.51x | 216.66x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
